Senate Bill 2028

	Legislative Session: 2024(2X)
LAST ACTION:	Effective from passage - (October 8, 2024)
SUMMARY:	Permitting development of opioid treatment program if part of clinical trial and approved by institutional review board
LEAD SPONSOR:	Blair (Mr. President)
SPONSORS:	Woelfel
BILL TEXT: Bill Definitions	Enrolled Version - html | pdf | docx Introduced Version - html | pdf | docx
CODE AFFECTED:	§16—2D—9 (Amended Code) §30—7—15A (Amended Code) §60A—9—4 (Amended Code)
FLOOR AMENDMENTS: Floor Amend. Definitions	sb2028 hfa akers and winzenreid 10-8 _3.htm sb2028 hfa akers and winzenreid 10-8 _3 adopted.htm sb2028 hfa akers and winzenreid 10-8 _2.htm sb2028 hfa akers and winzenreid 10-8 _1.htm sb2028 hfat akers.htm sb2028 hfat akers adopted.htm sb2028 hfat rohrbach _2.htm sb2028 hfa heckert 10-8 _3.htm sb2028 hfa heckert 10-8 _3 adopted.htm sb2028 hfat heckert.htm sb2028 hfa heckert 10-8 _2.htm sb2028 hfat rohrbach 10-8.htm sb2028 hfa heckert 10-8 _1.htm sb2028 hfa rohrbach 10-8 _1.htm
SIMILAR TO:	HB228
SUBJECT(S):	Governor -- Bills Requested By Health